- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05641142
Prospective Study of Antiplatelet and Anticoagulation Therapy in Hereditary Haemorrhagic Telangiectasia (PROPLACO-Tel)
Study Overview
Status
Detailed Description
Currently there are no recommendations on the use of anticoagulant and/or antiplatelet treatment in patients with Rendu-Osler Disease.
The main question this study aims to answer is:
• to better determine which anticoagulant and/or antiplatelet therapy are best tolerated or if they are equivalent in Rendu-Osler disease because this type of treatment is often used in urgent and/or vital situations.
Participants will have a 2-year follow-up with biological monitoring of ferritin and hemoglobin level and ESS (Epistaxis Severity Score) and QoL-HHT (Quality of Life Hereditary Hemorrhagic Telangiectasia) questionnaires.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Lise Laclautre
- Phone Number: 334.73.754.963
- Email: promo_interne_drci@chu-clermontferrand.fr
Study Locations
-
-
-
Angers, France
- Not yet recruiting
- CHU d'Angers
-
Contact:
- Lise Laclautre
-
Principal Investigator:
- Christian LAVIGNE
-
Bordeaux, France
- Not yet recruiting
- CHU de Bordeaux
-
Principal Investigator:
- Pierre DUFFAU
-
Contact:
- Lise Laclautre
-
Boulogne-Billancourt, France
- Not yet recruiting
- Hopital Ambroise Pare
-
Contact:
- Sandra Blivet
-
Contact:
- Lise Laclautre
-
Caen, France
- Not yet recruiting
- Chu de Caen Normandie
-
Principal Investigator:
- Laurent Chaussavoine
-
Contact:
- Lise Laclautre
-
Clermont-Ferrand, France
- Recruiting
- Chu Clermont-Ferrand
-
Contact:
- Lise Laclautre
-
Principal Investigator:
- Vincent GROBOST
-
Dijon, France
- Not yet recruiting
- CHU de Dijon
-
Principal Investigator:
- Hélène GREIGERT
-
Contact:
- Lise Laclautre
-
Lille, France
- Not yet recruiting
- CHRU de Lille
-
Principal Investigator:
- Hélène Maillard
-
Contact:
- Lise Laclautre
-
Lyon, France
- Not yet recruiting
- Hospices Civiles de Lyon
-
Principal Investigator:
- Sophie Dupuis-Girod
-
Contact:
- Lise Laclautre
-
Marseille, France
- Not yet recruiting
- Assistance Publique - Hopitaux de Marseille
-
Contact:
- Lise Laclautre
-
Principal Investigator:
- Baptiste André
-
Montpellier, France
- Not yet recruiting
- CHU de Montpellier
-
Principal Investigator:
- Sophie Rivière
-
Contact:
- Lise Laclautre
-
Nancy, France
- Not yet recruiting
- Chu de Nancy
-
Principal Investigator:
- Shirine MOHAMED
-
Contact:
- Lise Laclautre
-
Nantes, France
- Not yet recruiting
- CHU de Nantes
-
Principal Investigator:
- Giovanni Gautier
-
Contact:
- Lise Laclautre
-
Nice, France
- Not yet recruiting
- CHU de Nice
-
Principal Investigator:
- Johana Pradelli
-
Contact:
- Lise Laclautre
-
Paris, France
- Not yet recruiting
- AP-HP - Hopital Tenon
-
Principal Investigator:
- Antoine PARROT
-
Contact:
- Lise Laclautre
-
Poitiers, France
- Not yet recruiting
- CHU de Poitiers
-
Principal Investigator:
- Xavier Le Guillou Horn
-
Contact:
- Lise Laclautre
-
Rennes, France
- Not yet recruiting
- CHU de Rennes
-
Principal Investigator:
- Mallorie KERJOUAN
-
Contact:
- Lise Laclautre
-
Strasbourg, France
- Not yet recruiting
- CHRU de Strasbourg
-
Principal Investigator:
- Murielle RONDEAU-LUTZ
-
Contact:
- Lise Laclautre
-
Toulouse, France
- Not yet recruiting
- CHU de Toulouse
-
Contact:
- Lise Laclautre
-
Principal Investigator:
- Laurent Alric
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patient with Rendu-Osler disease with an indication of antiplatelet and/or anticoagulant introduced for less than 3 months (inclusion period within 3 months of exposure)
- Age > 18 years old
- Patient able to understand and agree to participate in the study
- Affiliation to a social security system
Exclusion Criteria:
- Patient with an indication of antiplatelet and/or anticoagulant but for whom treatment has not been introduced or introduced for more than 3 months
- Refusal to participate
- Pregnant woman or who are breast feeding
- Patients under maintenance of justice, wardship or legal guardianship
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Cohort study
a single arm, the anticoagulant and/or antiplatelet treatment is not conditioned by the study
|
Monitoring:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of transfusions and/or intravenous iron
Time Frame: 3 months after exposure to anticoagulants and/or antiplatelet
|
Number of transfusions and/or intravenous iron before (3 months) and within 3 months after exposure to anticoagulants and/or antiplatelet in patients with Rendu-Osler disease.
|
3 months after exposure to anticoagulants and/or antiplatelet
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Biological parameters
Time Frame: 3 months after exposure to anticoagulants and/or antiplatelet
|
Evolution of ferritin levels.
|
3 months after exposure to anticoagulants and/or antiplatelet
|
Biological parameters
Time Frame: 3 months after exposure to anticoagulants and/or antiplatelet
|
Evolution of hemoglobin levels.
|
3 months after exposure to anticoagulants and/or antiplatelet
|
Bleeding
Time Frame: 3 months after exposure to anticoagulants and/or antiplatelet
|
Onset of digestive bleeding and/or occurrence of a new hemorrhagic accident or major hemorrhagic event and/or hospitalisation for hemorrhage.
|
3 months after exposure to anticoagulants and/or antiplatelet
|
Anticoagulant and/or antiplatelet treatment
Time Frame: week 104 after patient inclusion
|
Frequency of continuation and/or modification and/or cessation of treatment if indication maintained.
|
week 104 after patient inclusion
|
Thrombotic accident
Time Frame: week 104 after patient inclusion
|
Frequency of occurrence of a new arterial and/or venous thrombotic accident and/or death
|
week 104 after patient inclusion
|
Epistaxis
Time Frame: week 12, 52 and 104 after patient inclusion
|
Evolution of epistaxis severity via ESS score
|
week 12, 52 and 104 after patient inclusion
|
Evaluation of Quality of life
Time Frame: week 6, 12, 52 and 104 after patient inclusion
|
Quality of life assessment via QoL-HHT questionnaire
|
week 6, 12, 52 and 104 after patient inclusion
|
Collaborators and Investigators
Investigators
- Principal Investigator: Vincent GROBOST, University Hospital, Clermont-Ferrand
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RBHP 2022 GROBOST
- 2022-A00754-39 (Other Identifier: 2022-A00754-39)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hereditary Hemorrhagic Telangiectasia
-
Vaderis Therapeutics AGRecruitingHereditary Hemorrhagic Telangiectasia (HHT)United States, Spain, France, Belgium, Netherlands, Italy
-
Unity Health TorontoSunnybrook Health Sciences Centre; University of Pittsburgh; Duke University; Barrow... and other collaboratorsActive, not recruitingHereditary Hemorrhagic Telangiectasia (HHT)Canada
-
Imperial College LondonCompletedHereditary Hemorrhagic Telangiectasia (HHT)United Kingdom
-
University Hospital, EssenCompletedHereditary Haemorrhagic Telangiectasia (HHT)Germany
-
University of PennsylvaniaCompletedHereditary Hemorrhagic Telangiectasia (HHT)United States
-
University Hospital, EssenCompleted
-
Centre Hospitalier Universitaire DijonCompletedHereditary Hemorrhagic TelangiectasiaFrance
-
Hospices Civils de LyonCompletedHHT | Hemorrhagic Hereditary TelangiectasiaFrance
-
Unity Health TorontoThe Hospital for Sick Children; Sunnybrook Health Sciences Centre; National Institute... and other collaboratorsCompletedHereditary Hemorrhagic TelangiectasiaCanada
-
Fondazione Policlinico Universitario Agostino Gemelli...CompletedHereditary Hemorrhagic TelangiectasiaItaly
Clinical Trials on monitoring the use of anticoagulant and/or antiplatelet therapy in patients with osler rendering disease
-
Memorial Sloan Kettering Cancer CenterNational Institutes of Health (NIH)Completed
-
Pharmicell Co., Ltd.TerminatedOvarian CancerKorea, Republic of
-
Hospital Mutua de TerrassaCompletedInflammatory Bowel Diseases | Hepatitis C Virus InfectionSpain
-
Federal Research Institute of Pediatric Hematology...Not yet recruitingAcute Lymphoblastic Leukemia, Pediatric | ALL, Infants
-
Memorial Sloan Kettering Cancer CenterTerminatedFibrillation | Post-Operative Cancer Patients Experiencing AtrialUnited States
-
Servier RussiaCompletedMyocardial Infarction | Coronary Artery Disease | Arterial HypertensionRussian Federation
-
Johannes Kepler University of LinzRecruiting
-
University of Texas Southwestern Medical CenterActive, not recruitingHead and Neck CancerUnited States
-
Centre hospitalier de l'Université de Montréal...WithdrawnRuptured Aneurysm of Intracranial ArteryCanada